Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00174200 |
To assess the effect of risperidone 2 mg daily (QD) on the differential sensitivity of 2 spatial working memory tests (the GMLT and MDR) in non-agitated, drug-naive patients suffering from first-episode schizophrenia/schizophreniform disorder.
Condition | Intervention |
---|---|
Schizophrenia Psychotic Disorders |
Drug: Risperidone 2 mg |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study |
Official Title: | A Randomized, Double-Blind, Crossover Add-On Study To Assess The Differential Sensitivity Of 2 Spatial Working Memory Tests (The Groton Maze Learning Test [GMLT] And The Motor Delayed Response Test [MDR]) In Non-Agitated, Antipsychotic Drug-Naive First-Episode Schizophrenic Or Schizophreniform Patients Treated With Risperidone 2 Mg Daily Or Placebo |
Estimated Enrollment: | 20 |
Study Start Date: | December 2004 |
Study Completion Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Nova Scotia | |
Pfizer Investigational Site | |
Dartmouth, Nova Scotia, Canada, B2Y 3Z9 | |
Pfizer Investigational Site | |
Halifax, Nova Scotia, Canada, B3H 2E2 | |
Russian Federation | |
Pfizer Investigational Site | |
Moscow, Russian Federation, 107076 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A9001229 |
Study First Received: | September 9, 2005 |
Last Updated: | July 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00174200 |
Health Authority: | Canada: Health Canada |
Schizophrenia Dopamine Mental Disorders Risperidone |
Psychotic Disorders Serotonin Schizophrenia and Disorders with Psychotic Features |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Serotonin Antagonists Serotonin Agents Therapeutic Uses Dopamine Agents Central Nervous System Agents |